Matinas BioPharma Holdings, Inc. (MTNB)
NYSEAMERICAN: MTNB · Real-Time Price · USD
0.1584
-0.0067 (-4.06%)
Sep 17, 2026, 9:39 AM EDT - Market open
Matinas BioPharma Holdings Earnings Call Transcripts
Fiscal Year 2024
-
A non-binding term sheet was signed for global MAT2203 licensing, with strong compassionate use results and a phase III trial expected to start in late 2024 or early 2025. Q2 net loss narrowed year-over-year, and cash was bolstered by a $10M offering.
-
MAT2203, an oral formulation of amphotericin B, addresses major limitations of current antifungal therapies by reducing toxicity and enabling outpatient treatment. Clinical data suggest strong efficacy and safety, with potential to capture significant market share if positive results continue.